
    
      The study aims to evaluate genetic markers (i.e. CTCs and ctDNA) in breast tumors to predict
      therapy response and metastatic risk. We aim to investigate genomic markers of treatment
      response and outcomes in breast cancer patients treated with neoadjuvant chemotherapy. The
      role of CTCs and ctDNA in predicting response to NAC will also be investigated.
    
  